Johnson & Johnson Consumer Inc. (J&JCI)
Trial Pipeline
A Study to Evaluate Usage of Mineral Sunscreens With Differentiated Whitening Attributes in Multi-Cultural Skin Tones
NCT06734299
Evaluation of the Acceptability and Feasibility of a Bedtime Routine for Neonates
NCT06318637
A Two-Week Study of an Anticavity Low pH Mouthwash
NCT06010758
A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area
NCT05226143
A Twelve Week Study of Virtually Supervised Mouth Rinse and Flossing
NCT04750005
Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque
NCT04921371
Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients
NCT03796052
A Twelve Week Study of Supervised Mouth Rinse and Flossing
NCT04696536
Pediatric Microbiome Study With Children Now Approximately 8-10 Years Old.
NCT03485755
Evaluation of Two Regimens, With Healthy Male and Female Babies, Ages 3-6 Months Old, Using Various Assessments.
NCT03457857
Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds
NCT03365934
A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris
NCT03128723
What the Pipeline for Johnson & Johnson Consumer Inc. (J&JCI) Shows
According to the ClinicalTrials.gov registry, Johnson & Johnson Consumer Inc. (J&JCI) is linked to 12 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 12 are already marked complete, representing roughly 100% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Johnson & Johnson Consumer Inc. (J&JCI) reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Johnson & Johnson Consumer Inc. (J&JCI) is Healthy with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.